Citations

Mayo Clinic

Clear

6050 citation(s) found for "Wu, Peter S".

Association of the PDYN gene with alcohol dependence and the propensity to drink in negative emotional states
Karpyak, Victor M. , Winham, Stacey J. , Preuss, Ulrich W. , Zill, Peter , Cunningham, Julie M. , Walker, Denise L., Lewis, Kriste A., Geske, Jennifer R. , Colby, Colin , Hall‐Flavin, Daniel K., Loukianova, Larissa L., Schneekloth, Terry D. , Frye, Mark A. , Bazov, Igor , Heit, John A. , Bakalkin, Georgy , Mrazek, David A. , Abulseoud, Osama A. , Biernacka, Joanna M. , Winham, Stacey J , Karpyak, Victor , Bakalkin, Georgy , Geske, Jennifer

International Journal of Neuropsychopharmacology | October 29, 2012 | Volume: 16 | Issue: 5 | Pages: 975-985

10.1017/s1461145712001137 | PMID 23101464 Get It

AbstractSynthetic κ-opioid receptor (KOR) agonists induce dysphoric and pro-depressive effects and variations in the KOR (OPRK1) and prodynorphin (PDYN) genes have been shown to be associated with alcohol dependence. We genotyped 23 single nucleotide polymorphisms (SNPs) in the PDYN and OPRK1 genes in 816 alcohol-dependent subjects and investigated their association with: (1) negative craving measured by a subscale of the Inventory of Drug Taking Situations; (2) a self-reported history of depression; (3) the intensity of depressive symptoms measured by the Beck Depression Inventory-II. In addition, 13 of the 23 PDYN and OPRK1 SNPs, which were previously genotyped in a set of 1248 controls, were used to evaluate association with alcohol dependence. SNP and haplotype tests of association were performed. Analysis of a haplotype spanning the PDYN gene (rs6045784, rs910080, rs2235751, rs2281285) revealed significant association with alcohol dependence (p = 0.00079) and with negative craving (p = 0.0499). A candidate haplotype containing the PDYN rs2281285-rs1997794 SNPs that was previously associated with alcohol dependence was also associated with negative craving (p = 0.024) and alcohol dependence (p = 0.0008) in this study. A trend for association between depression severity and PDYN variation was detected. No associations of OPRK1 gene variation with alcohol dependence or other studied phenotypes were found. These findings support the hypothesis that sequence variation in the PDYN gene contributes to both alcohol dependence and the induction of negative craving in alcohol-dependent subjects.
Cell Migration after Synovium Graft Interposition at Tendon Repair Site
Hayashi, Masanori , Zhao, Chunfeng , An, Kai‐Nan , Amadio, Peter C.

HAND | October 22, 2012 | Volume: 7 | Issue: 4 | Pages: 374-379

10.1007/s11552-012-9453-x | PMID 24294156 Get It

Background We have recently reported that interpositional synovium grafts from tendon sheath have a potential to accelerate tendon healing when implanted at the repair site. The purpose of this study was to investigate the effect of orientation of the synovium after synovium graft transplantation, by comparing the ability of cells from the visceral and parietal surfaces to migrate into the tendon in a canine tissue culture model. Methods The synovium graft was placed within a complete tendon laceration, with either the visceral or parietal surface facing the proximal end of the lacerated tendon. The number of migrating cells was quantified by a cell migration assay. Qualitative immunohistochemistry and confocal laser microscopy were also used at day 10. Results Many labeled synovial cells were observed within the tendon to which the visceral surface of the synovium graft was facing. Migrated cells were also observed on the parietal side, but there were fewer cells compared to visceral surface cells. Migrating cells all expressed α-smooth muscle actin. Conclusion We found that graft orientation affected cell migration. Whether this finding has clinical significance awaits in vivo study.
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
Emanuel, Robyn M., Dueck, Amylou C. , Geyer, Holly L. , Kiladjian, Jean‐Jacques , Slot, Stefanie , Boekhorst, Peter A.W. te , Commandeur, Suzan, Schouten, Harry C. , Sackmann, Federico, Fuentes, Ana Kerguelen, Hernández‐Maraver, Dolores , Pahl, Heike L. , Grießhammer, Martin , Stegelmann, Frank , Doehner, Konstanze, Lehmann, Thomas , Bonatz, Karin, Reiter, Andreas , Boyer, Françoise, Étienne, Gabriel , Ianotto, Jean‐Christophe , Ranta, Dana, Roy, Lydia , Cahn, Jean‐Yves, Harrison, Claire , Radia, Deepti , Muxí, Pablo , Besses, Carlos , Cervantes, Francisco , Johansson, Peter , Barbui, Tiziano , Passamonti, Francesco , Andréasson, Björn , Ferarri, Maria L, Rambaldi, Alessandro , Samuelsson, Jan , Birgegård, Gunnar , Tefferi, Ayalew , Zweegman, Sonja , Maldonado, Norman D. , Barosi, Giovanni , Vannucchi, Alessandro M. , Mesa, Ruben A. , Dueck, A. C. , Kiladjian, Jean-Jacques , Rambaldi, Alessandro , Ianotto, Jean-Christophe , Passamonti, Francesco

Journal of Clinical Oncology | October 16, 2012 | Volume: 30 | Issue: 33 | Pages: 4098-4103

10.1200/jco.2012.42.3863 | PMID 23071245 Get It

Purpose Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this burden represents a paramount treatment objective in the development of MPN-directed therapies. We aimed to assess the utility of an abbreviated symptom score for the most pertinent and representative MPN symptoms for subsequent serial use in assessing response to therapy. Patients and Methods The Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (MPN-SAF TSS) was calculated as the mean score for 10 items from two previously validated scoring systems. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers. Results MPN-SAF TSS was calculable for 1,408 of 1,433 patients with MPNs who had a mean score of 21.2 (standard deviation [SD], 16.3). MPN-SAF TSS results significantly differed among MPN disease subtypes (P < .001), with a mean of 18.7 (SD, 15.3), 21.8 (SD, 16.3), and 25.3 (SD, 17.2) for patients with essential thrombocythemia, polycythemia vera, and myelofibrosis, respectively. The MPN-SAF TSS strongly correlated with overall quality of life (QOL; r = 0.59; P < .001) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) functional scales (all P < .001 and absolute r ≥ 0.50 except social functioning r = 0.48). No significant trends were present when comparing therapy subgroups. The MPN-SAF TSS had excellent internal consistency (Cronbach's α = .83). Factor analysis identified a single underlying construct, indicating that the MPN-SAF TSS is an appropriate, unified scoring method. Conclusion The MPN-SAF TSS is a concise, valid, and accurate assessment of MPN symptom burden with demonstrated clinical utility in the largest prospective MPN symptom study to date. This new prospective scoring method may be used to assess MPN symptom burden in both clinical practice and trial settings.
A Novel Disease Gene for Brugada Syndrome
Ishikawa, Taisuke , Marcou, Cherisse A. , Tester, David J. , Ackerman, Michael J. , Crotti, Lia , Schwartz, Peter J. , Park, Jeong-Euy, Nakamura, Kazufumi , Hiraoka, Masayasu , Nakazawa, Kiyoshi, Sakurada, Harumizu, Arimura, Takuro , Makita, Naomasa , Ishikawa, Taisuke , Sato, Akinori , Crotti, Lia , Schwartz, Peter J. , On, Young Keun , Makita, Naomasa , Kimura, Akinori

Circulation: Arrhythmia and Electrophysiology | October 13, 2012 | Volume: 5 | Issue: 6 | Pages: 1098-1107

10.1161/circep.111.969972 | PMID 23064965 Get It

Background— Mutations in genes including SCN5A encoding the α-subunit of the cardiac sodium channel (hNav1.5) cause Brugada syndrome via altered function of cardiac ion channels, but more than two-thirds of Brugada syndrome remains pathogenetically elusive. T-tubules and sarcoplasmic reticulum are essential in excitation of cardiomyocytes, and sarcolemmal membrane-associated protein (SLMAP) is a protein of unknown function localizing at T-tubules and sarcoplasmic reticulum. Methods and Results— We analyzed 190 unrelated Brugada syndrome patients for mutations in SLMAP . Two missense mutations, Val269Ile and Glu710Ala, were found in heterozygous state in 2 patients but were not found in healthy individuals. Membrane surface expression of hNav1.5 in the transfected cells was affected by the mutations, and silencing of mutant SLMAP by small interfering RNA rescued the surface expression of hNav1.5. Whole-cell patch-clamp recordings of hNav1.5-expressing cells transfected with mutant SLMAP confirmed the reduced hNav1.5 current. Conclusions— The mutations in SLMAP may cause Brugada syndrome via modulating the intracellular trafficking of hNav1.5 channel.
Rare variants in XRCC2 as breast cancer susceptibility alleles: Table 1
Hilbers, Florentine , Hoogerbrugge, Nicoline, Oosterwijk, Jan C., Collée, Margriet J., Peterlongo, Paolo , Radice, Paolo , Manoukian, Siranoush , Feroce, Irène , Capra, F, Guidugli, Lucia, Offit, Kenneth, Shah, Sohela, Campbell, Ian , Thompson, Ella R. , James, Paul A. , Trainer, Alison H., Gracia, Javier, Devilee, Peter , Hoogerbrugge, Nicoline , Wijnen, Juul , Hoogerbrugge, Nicoline, Collée, Margriet , Couch, Fergus J. , Wang, Xianshu , Benı́tez, Javier , Asperen, Christi J. van , James, Paul , Peterlongo, Paolo , Radice, Paolo , Campbell, Ian G , Devilee, Peter , Manoukian, Siranoush

Journal of Medical Genetics | October 10, 2012 | Volume: 49 | Issue: 10 | Pages: 618-620

10.1136/jmedgenet-2012-101191 | PMID 23054243 Get It

Background Recently, rare germline variants in XRCC2 were detected in non-BRCA1/2 familial breast cancer cases, and a significant association with breast cancer was reported. However, the breast cancer risk associated with these variants needs further evaluation. Methods The coding regions and exon–intron boundaries of XRCC2 were scanned for mutations in an international cohort of 3548 non-BRCA1/2 familial breast cancer cases and 1435 healthy controls using various mutation scanning methods. Predictions on functional relevance of detected missense variants were obtained from three different prediction algorithms. Results The only protein-truncating variant detected was found in a control. Rare non-protein-truncating variants were detected in 20 familial cases (0.6%) and nine healthy controls (0.6%). Although the number of variants predicted to be damaging or neutral differed between prediction algorithms, in all instances these categories were evenly represented among cases and controls. Conclusions Our data do not confirm an association between XRCC2 variants and breast cancer risk, although a relative risk smaller than two could not be excluded. Variants in XRCC2 are unlikely to explain a substantial proportion of familial breast cancer.
Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Results from a randomized, multicenter, double-blinded, controlled study
Silberstein, Stephen D., Saper, Joel R., Huh, Billy , Sharan, Ashwini , Reed, K. L. , Mogilner, Alon Y. , Goldstein, Jerome , Trentman, Terrence L. , Vaisman, Julien, Ordia, Joseph, Weber, Peter, Levy, Robert M. , Diaz, Roni L, Washburn, Stephanie N., Dodick, David W. , Slavin, Konstantin V. , Narouze, Samer , Weber, Peter, Deer, Timothy R. , Diaz, Roni L., Mekhail, Nagy

Cephalalgia | October 4, 2012 | Volume: 32 | Issue: 16 | Pages: 1165-1179

10.1177/0333102412462642 | PMID 23034698 Get It

Background: Chronic migraine (CM) is a debilitating neurological disorder with few treatment options. Peripheral nerve stimulation (PNS) of the occipital nerves is a potentially promising therapy for CM patients. Methods: In this randomized, controlled multicenter study, patients diagnosed with CM were implanted with a neurostimulation device near the occipital nerves and randomized 2:1 to active ( n = 105) or sham ( n = 52) stimulation. The primary endpoint was a difference in the percentage of responders (defined as patients that achieved a ≥50% reduction in mean daily visual analog scale scores) in each group at 12 weeks. Results: There was not a significant difference in the percentage of responders in the Active compared with the Control group (95% lower confidence bound (LCB) of −0.06; p = 0.55). However, there was a significant difference in the percentage of patients that achieved a 30% reduction ( p = 0.01). Importantly, compared with sham-treated patients, there were also significant differences in reduction of number of headache days (Active Group = 6.1, baseline = 22.4; Control Group = 3.0, baseline = 20.1; p = 0.008), migraine-related disability ( p = 0.001) and direct reports of pain relief ( p = 0.001). The most common adverse event was persistent implant site pain. Conclusion: Although this study failed to meet its primary endpoint, this is the first large-scale study of PNS of the occipital nerves in CM patients that showed significant reductions in pain, headache days, and migraine-related disability. Additional controlled studies using endpoints that have recently been identified and accepted as clinically meaningful are warranted in this highly disabled patient population with a large unmet medical need. Trial registration: Clinical trials.gov (NCT00615342).
Longitudinal Studies of Cardiac Troponin I in a Large Cohort of Healthy Children
Koerbin, Gus, Potter, Julia M. , Abhayaratna, Walter P. , Telford, Richard D. , Apple, Fred S. , Jaffe, Allan S. , Hickman, Peter E. , Badrick, Tony C , Jaffe, Allan S. , Abhayaratna, Walter

Clinical Chemistry | September 28, 2012 | Volume: 58 | Issue: 12 | Pages: 1665-1672

10.1373/clinchem.2012.192054 | PMID 23019308 Get It

BACKGROUND There is little information available on cardiac troponin concentrations in healthy young children. METHODS Using a precommercial high-sensitivity assay from Abbott Diagnostics, we measured cardiac troponin I (cTnI) in longitudinal blood samples collected at ages 8, 10, and 12 years from a cohort of healthy, community-dwelling children. The 99th percentile values were calculated and estimates of the long-term biological variation were made. RESULTS cTnI concentrations were above the limit of detection in 87%, 90%, and 98% of the children at ages 8, 10, and 12 years. The 99th percentiles were lower compared to a healthy adult population in both male and female children at all ages studied. At the 3 periods of study assessment, different children had cTnI concentrations above the 99th percentile. The calculated 99th percentile varied markedly depending upon whether the lowest or highest cTnI measurement for an individual child was included in the calculation. Biological variation varied markedly between 0% and 136%, the index of individuality was low at 0.36, and the reference change value was an increase of 147% or a decrease of 59%. CONCLUSIONS In this longitudinal study of cTnI concentrations in healthy children as determined by a high-sensitivity assay, different children had concentrations of cTnI above the 99th percentile at the 3 episodes of assessment. These results suggest that in children the 99th percentile may not be a reliable index of silent cardiac disease, but rather may be indicating low-grade intercurrent illness.
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
Klyuchnikov, Evgeny , Carreras, Jeanette, Armand, Philippe , Bishop, Michael, Bredeson, Christopher , Cairo, Mitchell S. , Fenske, Timothy S. , Freytes, César O. , Gibson, John, Isola, Luis , Inwards, David J. , Laport, Ginna G. , Wiernik, Peter H. , Schouten, Harry C. , Slavin, Shimon, Smith, Sonali M. , Waller, Edmund K. , Hari, Parameswaran , Bacher, Ulrike , Le‐Rademacher, Jennifer , Gale, Robert Peter , Lazarus, Hillard M. , Maziarz, Richard Thomas , Vose, Julie M. , Waller, Edmund K , Hari, Parameswaran

Blood | September 25, 2012 | Volume: 120 | Issue: 20 | Pages: 4256-4262

10.1182/blood-2012-06-436725 | PMID 23007405 Get It

Abstract The best conditioning regimen before allogeneic transplantation for high-risk diffuse large B-cell lymphoma (DLBCL) remains to be clarified. We analyzed data from 396 recipients of allotransplants for DLBCL receiving myeloablative (MAC; n = 165), reduced intensity (RIC; n = 143), or nonmyeloablative conditioning (NMAC; n = 88) regimens. Acute and chronic GVHD rates were similar across the groups. Five-year nonrelapse mortality (NRM) was higher in MAC than RIC and NMAC (56% vs 47% vs 36%; P = .007). Five-year relapse/progression was lower in MAC than in RIC/NMAC (26% vs 38% vs 40%; P = .031). Five-year progression-free survival (15%-25%) and overall survival (18%-26%) did not differ significantly between the cohorts. In multivariate analysis, NMAC and more recent transplant year were associated with lower NRM, whereas a lower Karnofsky performance score (< 90), prior relapse resistant to therapy, and use of unrelated donors were associated with higher NRM. NMAC transplants, no prior use of rituximab, and prior relapse resistant to therapy were associated with a greater risk of relapse/progression. In conclusion, allotransplantation with RIC or NMAC induces long-term progression-free survival in selected DLBCL patients with a lower risk of NRM but with higher risk of lymphoma progression or relapse.
Analysis of the impact of intravenous LH pulses versus continuous LH infusion on testosterone secretion during GnRH-receptor blockade
Veldhuis, Johannes D. , Liu, Peter Y. , Takahashi, Paul Y. , Weist, Suanne M., Wigham, Jean, Takahashi, Paul

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | September 19, 2012 | Volume: 303 | Issue: 10 | Pages: R994-R1002

10.1152/ajpregu.00314.2012 | PMID 22992702 Get It

Gonadotrophin-releasing hormone (GnRH) pulsatility is required for optimal luteinizing hormone (LH) secretion, but whether LH pulsatility is required for physiological testosterone (T) secretion is not known. To test the postulate that pulses of recombinant human (rh) LH stimulate greater T secretion than continuous infusion of the same dose, a potent selective GnRH antagonist was administered overnight to 19 healthy men ages 18–49 yr. Subjects then received saline or rhLH intravenously continuously or as 6-min pulses intravenously every 1 or 2 h at the same total dose. Blood was sampled every 10 min for 10 h to quantify T responses. For the four interventions, the descending rank order of mean LH and mean T concentrations was 1-h = 2-h rhLH pulses > continuous rhLH > saline ( P < 10−3). Plateau LH and T concentrations correlated positively ( R2 = 0.943, P = 0.029) as did LH concentrations and LH half-lives ( R2 = 0.962, P = 0.019). Percentage pulsatile T secretion assessed by deconvolution analysis (Keenan DM, Takahashi PY, Liu PY, Roebuck PD, Nehra AX, Iranmanesh A, Veldhuis JD. Endocrinology 147: 2817–2828, 2006) was the highest ( P = 0.019), and half-time to attain peak T concentrations was the shortest ( P < 10−6), for 1-h rhLH pulses. Approximate entropy (a pattern-regularity measure) revealed more orderly T secretion for 1- than 2-h rhLH pulses ( P = 0.0076). Accordingly, a pulsatile LH signal, while not obligatory to maintain mean T concentrations, controls the mean plasma LH concentration and determines quantifiable patterns of T secretion. These data introduce the question whether blood T patterns in turn supervise distinctive target-tissue responses.